Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Francesco Berluti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Pyrazoles, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alexander von Humboldt-Stiftung, Deutsche Forschungsgemeinschaft, German Research Foundation DFG project.
Abstract (Originalsprache)
Class I histone deacetylases (HDACs) are considered promising targets in current cancer research. To obtain subtype‐selective and potent HDAC inhibitors, we used the aminobenzamide scaffold as the zinc‐binding group and prepared new derivatives with a pyrazole ring as the linking group. The synthesized compounds were analyzed in vitro using an enzymatic assay against HDAC1, −2, and −3. Compounds 12b , 15b , and 15i were found to be potent HDAC1 inhibitors, also in comparison to the reference compounds entinostat and tacedinaline, with IC 50 values of 0.93, 0.22, and 0.68 μM, respectively. The best compounds were measured for their cellular effect and target engagement in acute myeloid leukemia (AML) cells. In addition, we studied the interaction of the compounds with HDAC subtypes using docking and molecular dynamic simulations. In summary, we have developed a new chemotype of HDAC1 inhibitors that can be used for further structure‐based optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Department of Molecular Medicine, Faculty of Medicine, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Department of Enzymology, Institute of Biochemistry, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
ORCID-Profile: Stefan Hüttelmaier, Mike Schutkowski
Förderung
- Alexander von Humboldt-Stiftung
- Deutsche Forschungsgemeinschaft
- German Research Foundation DFG project
- Alexander von Humboldt Foundation project EGY
Zitieren
APA
Berluti, F., Baselious, F., Hagemann, S., Hilscher, S., Schmidt, M., Hüttelmaier, S., Schutkowski, M., Sippl, W., & Ibrahim, H. S. (2024). Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400437
Vancouver
Berluti F, Baselious F, Hagemann S, Hilscher S, Schmidt M, Hüttelmaier S, et al. Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400437
BibTeX
@article{Berluti2024,
author = {Berluti, Francesco and Baselious, Fady and Hagemann, Sven and Hilscher, Sebastian and Schmidt, Matthias and Hüttelmaier, Stefan and Schutkowski, Mike and Sippl, Wolfgang and Ibrahim, Hany S},
title = {Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400437}
}
EUVIMED